Loading
A phase 3 trial of Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT04834024 by Beijing Mabworks Biotech Co., Ltd., with 168 participants planned, started 2021-06-02 and due to reach its primary completion in 2025-03. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide and lenalinomide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Mabworks Biotech and the tag pipeline.
Shares Beijing Mabworks Biotech and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/